Stocks and Investing Stocks and Investing
Fri, February 9, 2018

Ami Fadia Maintained (TEVA) at Sell with Decreased Target to $16 on, Feb 9th, 2018


Published on 2024-10-26 02:49:37 - WOPRAI, Ami Fadia
  Print publication without navigation


Ami Fadia of Leerink Swann, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Sell with Decreased Target from $17 to $16 on, Feb 9th, 2018.

Ami has made no other calls on TEVA in the last 4 months.



There are 10 other peers that have a rating on TEVA. Out of the 10 peers that are also analyzing TEVA, 5 agree with Ami's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Tim Chiang of "BTIG" Downgraded from Strong Buy to Hold on, Thursday, January 18th, 2018
  • Vamil Divan of "Credit Suisse" Upgraded from Sell to Hold on, Friday, December 15th, 2017
  • David Risinger of "Morgan Stanley" Upgraded from Sell to Hold on, Friday, December 15th, 2017
  • Rohit Vanjani of "Guggenheim" Initiated at Hold and Held Target at $16 on, Tuesday, December 12th, 2017
  • Douglas Tsao of "Barclays" Maintained at Hold with Decreased Target to $19 on, Friday, October 20th, 2017


These are the ratings of the 5 analyists that currently disagree with Ami


  • Irina Rivkind Koffler of "Mizuho" Upgraded from Hold to Strong Buy on, Tuesday, January 9th, 2018
  • Jacob Hughes of "Wells Fargo" Downgraded from Hold to Sell on, Friday, January 5th, 2018
  • Liav Abraham of "Citigroup" Upgraded from Hold to Strong Buy on, Thursday, January 4th, 2018
  • Jami Rubin of "Goldman Sachs" Upgraded from Hold to Strong Buy on, Friday, December 15th, 2017
  • Chris Schott of "JP Morgan" Downgraded from Hold to Sell on, Monday, November 13th, 2017
Contributing Sources